Literature DB >> 17356917

Intestinal permeability and antigliadin antibody test for monitoring adult patients with celiac disease.

Eduardo Garcia Vilela1, Maria de Lourdes de Abreu Ferrari, Henrique Osvaldo de Gama Torres, Fabiana Paiva Martins, Eugênio Marcos Andrade Goulart, Agnaldo Soares Lima, Aloíso Sales da Cunha.   

Abstract

Celiac disease causes chronic inflammation of the intestinal mucosa and reduces surface absorption; after the withdrawal of gluten from the diet, there are clinical and histologic improvements. The intestinal permeability test and serologic tests are useful for confirming the diagnosis and monitoring patients. The goal of this study is to compare the antigliadin antibody (AGA) test with the intestinal permeability test for celiac patients on a gluten-free diet. The sample consisted of 22 celiac patients who were antigliadin immunoglobulin A-positive before treatment. After 12 months on a gluten-free diet, AGA testing was repeated and the intestinal permeability test was performed. A control group was composed of 11 healthy individuals. AGA remained positive in 40.9% of celiac patients, and the mean urinary lactulose excretion was 10.27%, that of mannitol was 10.18%, and the lactulose/mannitol ratio was 1.02. In the subgroup in which antigliadin became negative (59.1%), the value for lactulose was 3.79%, that for mannitol was 11.12%, the lactulose/mannitol ratio was 0.38, and the p value was less than 0.0001, 0.66, and less than 0.0001, respectively. When the two celiac subgroups were compared with the control group, the urinary lactulose excretion and the lactulose/mannitol ratio was less in the control group, whereas urinary mannitol excretion was greater. The p values were less than 0.0001 for the three variables, suggesting persistent lesions in mucosa of both subgroups, although to a lesser degree for those that became AGA negative. It is concluded that intestinal permeability allows a more precise clinical physiopathologic correlation than antigliadin and offers more information for the monitoring of these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356917     DOI: 10.1007/s10620-006-9511-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  35 in total

Review 1.  Reliance on serum endomysial antibody testing underestimates the true prevalence of coeliac disease by one fifth.

Authors:  W Dickey; D F Hughes; S A McMillan
Journal:  Scand J Gastroenterol       Date:  2000-02       Impact factor: 2.423

2.  Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice.

Authors:  K Rostami; J Kerckhaert; R Tiemessen; B M von Blomberg; J W Meijer; C J Mulder
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

Review 3.  Celiac sprue.

Authors:  Richard J Farrell; Ciarán P Kelly
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

4.  Intestinal permeability: functional assessment and significance.

Authors:  S Travis; I Menzies
Journal:  Clin Sci (Lond)       Date:  1992-05       Impact factor: 6.124

5.  Abnormal intestinal permeability and jejunal morphometry.

Authors:  L D Juby; M F Dixon; A T Axon
Journal:  J Clin Pathol       Date:  1987-07       Impact factor: 3.411

Review 6.  Intestinal permeation and gastrointestinal disease.

Authors:  Mark T DeMeo; Ece A Mutlu; Ali Keshavarzian; Mary C Tobin
Journal:  J Clin Gastroenterol       Date:  2002-04       Impact factor: 3.062

7.  Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease.

Authors:  A Fasano; T Not; W Wang; S Uzzau; I Berti; A Tommasini; S E Goldblum
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

8.  Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet.

Authors:  D R Duerksen; C Wilhelm-Boyles; D M Parry
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 9.  Coeliac disease: dissecting a complex inflammatory disorder.

Authors:  Ludvig M Sollid
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

10.  Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers.

Authors:  J L Madara; J Stafford
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

View more
  7 in total

1.  Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease.

Authors:  B N Spatola; K Kaukinen; P Collin; M Mäki; M F Kagnoff; P S Daugherty
Journal:  Aliment Pharmacol Ther       Date:  2014-01-06       Impact factor: 8.171

Review 2.  The measurement and clinical significance of intestinal permeability.

Authors:  Christopher W Teshima; Jon B Meddings
Journal:  Curr Gastroenterol Rep       Date:  2008-10

Review 3.  Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis.

Authors:  Jocelyn A Silvester; Satya Kurada; Andrea Szwajcer; Ciarán P Kelly; Daniel A Leffler; Donald R Duerksen
Journal:  Gastroenterology       Date:  2017-05-22       Impact factor: 22.682

4.  A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet.

Authors:  D R Duerksen; C Wilhelm-Boyles; R Veitch; D Kryszak; D M Parry
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

5.  The Role of an IgA/IgG-Deamidated Gliadin Peptide Point-of-Care Test in Predicting Persistent Villous Atrophy in Patients With Celiac Disease on a Gluten-Free Diet.

Authors:  Michelle S Lau; Peter D Mooney; William L White; Michael A Rees; Simon H Wong; Matthew Kurien; Nick Trott; Daniel A Leffler; Marios Hadjivassiliou; David S Sanders
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

Review 6.  Diploid Wheats: Are They Less Immunogenic for Non-Celiac Wheat Sensitive Consumers?

Authors:  Vera Rotondi Aufiero; Anna Sapone; Giuseppe Mazzarella
Journal:  Cells       Date:  2022-08-03       Impact factor: 7.666

7.  Oats in the diet of children with celiac disease: preliminary results of a double-blind, randomized, placebo-controlled multicenter Italian study.

Authors:  Simona Gatti; Nicole Caporelli; Tiziana Galeazzi; Ruggiero Francavilla; Maria Barbato; Paola Roggero; Basilio Malamisura; Giuseppe Iacono; Andrea Budelli; Rosaria Gesuita; Carlo Catassi; Elena Lionetti
Journal:  Nutrients       Date:  2013-11-20       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.